CLDX
Celldex Therapeutics Inc
37.90$
-0.9%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 82.7% | 87.4% | 51.0% | 45.9% | 63.6% | 54.3% | 83.9% | 92.4% | 90.1% | 92.7% | 94.3% | 91.7% | |
| 11.3% | 21.4% | 11.1% | 12.8% | 15.6% | 9.1% | 18.6% | 8.8% | 8.3% | 7.5% | 3.6% | 5.0% | |
| 81.1% | 85.9% | 49.5% | 44.2% | 60.3% | 52.2% | 82.4% | 91.8% | 86.5% | 90.6% | 91.5% | 89.0% | |
| 0.2% | 0.3% | 0.5% | 0.6% | 2.0% | 1.0% | 0.8% | 0.0% | 0.1% | 1.0% | 0.1% | 0.3% | |
| -0.2% | -0.3% | -0.5% | 0.0% | -2.0% | -0.8% | -0.8% | 0.0% | -0.1% | 0.0% | – | – | |
| 4.2% | 3.4% | 3.4% | 3.3% | 3.9% | 3.3% | 3.1% | 1.5% | 2.2% | – | – | – | |
| 3.6% | 2.7% | 23.7% | 28.8% | 0.0% | – | – | – | – | – | – | – | |
| 8.8% | 6.2% | 21.3% | 21.4% | 32.5% | 39.6% | 13.0% | 6.1% | 7.7% | 5.8% | 3.4% | 4.7% | |
| 14.7% | 14.1% | 30.8% | 25.1% | 20.4% | 23.5% | 11.2% | 5.7% | 7.5% | 7.8% | 5.7% | 9.6% | |
| 9.9% | 9.0% | 9.2% | 8.8% | 8.1% | 9.5% | 6.0% | 3.7% | 5.3% | 6.7% | 5.0% | 8.7% | |
| 1.0% | 1.3% | 1.3% | 2.1% | 2.9% | 1.6% | 0.6% | 0.4% | 0.4% | 0.3% | 0.2% | 0.3% | |
| 1.0% | 0.4% | 0.5% | 0.5% | 0.7% | 1.0% | 0.4% | 0.3% | 0.9% | 0.8% | 0.4% | 0.2% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 85.3% | 85.9% | 69.2% | 74.9% | 79.6% | 76.5% | 88.8% | 94.3% | 92.5% | 92.2% | 94.3% | 90.4% | |
| -187.0% | -175.1% | -187.7% | -257.4% | -617.7% | -824.3% | -455.0% | -257.2% | -356.1% | -300.1% | -196.3% | -311.2% | |
| 2.4% | 1.9% | 1.8% | 2.7% | 6.7% | 11.8% | 12.6% | 9.6% | 13.3% | 10.4% | 8.1% | 11.4% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.